CA2413354C - Neurotoxic a.beta. oligomers in alzheimer's disease - Google Patents
Neurotoxic a.beta. oligomers in alzheimer's disease Download PDFInfo
- Publication number
- CA2413354C CA2413354C CA2413354A CA2413354A CA2413354C CA 2413354 C CA2413354 C CA 2413354C CA 2413354 A CA2413354 A CA 2413354A CA 2413354 A CA2413354 A CA 2413354A CA 2413354 C CA2413354 C CA 2413354C
- Authority
- CA
- Canada
- Prior art keywords
- beta
- tyrosine
- antibody
- disease
- cross
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21477900P | 2000-06-28 | 2000-06-28 | |
| US60/214,779 | 2000-06-28 | ||
| US24217700P | 2000-10-23 | 2000-10-23 | |
| US60/242,177 | 2000-10-23 | ||
| PCT/AU2001/000786 WO2002000245A1 (en) | 2000-06-28 | 2001-06-28 | Neurotoxic oligomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2413354A1 CA2413354A1 (en) | 2002-01-03 |
| CA2413354C true CA2413354C (en) | 2014-04-01 |
Family
ID=26909346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2413354A Expired - Fee Related CA2413354C (en) | 2000-06-28 | 2001-06-28 | Neurotoxic a.beta. oligomers in alzheimer's disease |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7618634B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1296705B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004501204A (cg-RX-API-DMAC7.html) |
| CN (2) | CN1450908A (cg-RX-API-DMAC7.html) |
| AU (2) | AU6882801A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2413354C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1296705T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2389811T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ523428A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002000245A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7955812B2 (en) | 2004-07-19 | 2011-06-07 | The General Hospital Corporation | Methods of diagnosing alzheimer's disease by detecting antibodies to cross-linked β-amyloid oligomers |
| US9335331B2 (en) * | 2005-04-11 | 2016-05-10 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| WO2007089335A2 (en) * | 2005-12-29 | 2007-08-09 | Lexicon Pharmaceutical Inc. | Multicyclic amino acid derivatives and methods of their use |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) * | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| WO2009048631A1 (en) * | 2007-10-11 | 2009-04-16 | University Of Tennessee Research Foundation | PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| JP2013511734A (ja) * | 2009-11-24 | 2013-04-04 | プロビオドルグ エージー | アルツハイマー病又は軽度認知障害の診断のための新規診断方法 |
| WO2011106732A1 (en) | 2010-02-25 | 2011-09-01 | Wyeth Llc | Pet monitoring of ab-directed immunotherapy |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CN112352170B (zh) * | 2018-05-15 | 2024-08-23 | 鲍希与洛姆伯股份有限公司 | 可水提取的眼用装置 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| DE102019129221B4 (de) | 2019-10-29 | 2022-05-12 | Chiracon Gmbh | Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
| CN117024554A (zh) * | 2023-05-30 | 2023-11-10 | 中国人民解放军空军军医大学 | 一种Aβ1-42寡聚体存储液的制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2001
- 2001-06-28 CN CN01813312A patent/CN1450908A/zh active Pending
- 2001-06-28 AU AU6882801A patent/AU6882801A/xx active Pending
- 2001-06-28 NZ NZ523428A patent/NZ523428A/en not_active IP Right Cessation
- 2001-06-28 US US10/312,437 patent/US7618634B2/en not_active Expired - Fee Related
- 2001-06-28 WO PCT/AU2001/000786 patent/WO2002000245A1/en not_active Ceased
- 2001-06-28 CN CN2008101298934A patent/CN101411876B/zh not_active Expired - Fee Related
- 2001-06-28 CA CA2413354A patent/CA2413354C/en not_active Expired - Fee Related
- 2001-06-28 AU AU2001268828A patent/AU2001268828C1/en not_active Ceased
- 2001-06-28 JP JP2002505026A patent/JP2004501204A/ja active Pending
- 2001-06-28 ES ES01947033T patent/ES2389811T3/es not_active Expired - Lifetime
- 2001-06-28 DK DK01947033.5T patent/DK1296705T3/da active
- 2001-06-28 EP EP01947033A patent/EP1296705B1/en not_active Expired - Lifetime
-
2009
- 2009-05-14 US US12/466,094 patent/US8318171B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1296705A1 (en) | 2003-04-02 |
| US20040013680A1 (en) | 2004-01-22 |
| US8318171B2 (en) | 2012-11-27 |
| CN101411876B (zh) | 2013-01-16 |
| DK1296705T3 (da) | 2012-09-17 |
| EP1296705A4 (en) | 2005-04-20 |
| EP1296705B1 (en) | 2012-06-13 |
| CA2413354A1 (en) | 2002-01-03 |
| WO2002000245A1 (en) | 2002-01-03 |
| AU6882801A (en) | 2002-01-08 |
| JP2004501204A (ja) | 2004-01-15 |
| NZ523428A (en) | 2008-03-28 |
| CN101411876A (zh) | 2009-04-22 |
| HK1131745A1 (en) | 2010-02-05 |
| CN1450908A (zh) | 2003-10-22 |
| ES2389811T3 (es) | 2012-10-31 |
| US20090297538A1 (en) | 2009-12-03 |
| AU2001268828C1 (en) | 2006-12-14 |
| US7618634B2 (en) | 2009-11-17 |
| AU2001268828B2 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8318171B2 (en) | Neurotoxic oligomers | |
| AU2001268828A1 (en) | Neurotoxic oligomers | |
| EP1497321B1 (en) | Immunological methods and compositions for the treatment of alzheimer's disease | |
| US8871447B2 (en) | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence | |
| AU2003250102B2 (en) | Fragments of beta-amyloid as targets for vaccination against alzheimer disease | |
| US9289488B2 (en) | Vaccine engineering | |
| US20110250217A1 (en) | Methods and compositions for eliciting an amyloid-selective immune response | |
| JP2016065100A (ja) | アルツハイマー病治療方法 | |
| MX2010013648A (es) | Compuestos para tratar enfermedades. | |
| Vingtdeux et al. | A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides | |
| CN116261464A (zh) | 免疫原性化合物 | |
| TW201018478A (en) | Immunotherapy compositions for the treatment and prevention of amyloidosis | |
| US20160303208A1 (en) | Method for treating amyloid disease | |
| Mruthinti et al. | Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites | |
| HK1131745B (en) | Neurotoxic oligomers | |
| HK1072947B (en) | Immunological methods and compositions for the treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190628 |